Main Research Areas (Recruitment Specialties) and Content
Primarily engaged in basic and translational research on cardiovascular diseases, with a particular focus on the role of organ interactions in metabolic-driven atherosclerotic cardiovascular diseases. Aspiration is to identify novel critical targets for complex cardiovascular diseases and explore effective prevention and treatment strategies through interdisciplinary research.
As a doctoral supervisor and adjunct professor, the individual was selected as a Young Talent in Science and Technology under the Tianjin Innovation Talent Promotion Program and awarded National Natural Science Foundation--Outstanding Youth Foundation. As the first author/corresponding author, the individual has published over 50 publications in top journals such as Nature Communications, Cell Reports, Journal of Hepatology, EMBO Reports, STTT, JBC, BJP, and ATVB. The individual has also secured the second awards for Natural Sciences in the Excellent Achievements of University Scientific Research and the third recognition in the Chinese Medical Science and Technology Awards.
Education and Work Experience
2000-2004: Nankai University, Bachelor of Science in Biological Sciences.
2004-2009: Nankai University, Ph.D. in Biochemistry and Molecular Biology.
2009-2015: Nankai University, Lecturer, Associate Researcher.
2015-2021: Hefei University of Technology, Professor.
2021-present: University of Science and Technology of China, Professor.
Academic Achievements and Impact
Primarily engaged in basic and applied research related to cardiovascular diseases, having supervised 10 doctoral and master's students. The applicant has published over 100 SCI papers with 1443 citations, among which more than 50 papers (including co-authored ones) were published as corresponding authors or first authors, such as in Nat Comm, Cell Rep, J Hepatol, APSB, ATVB, JBC and Br J Pharmacol . Representative papers in the last five years include:
1. Xue C#, Zeng P#, Gong K, Li Q, Feng Z, Wang M, Chen S, Yang Y, Li J, Zhang S, Yin Z, Liang Y, Yan T, Yu M, Feng K, Zhao D, Yang X, Zhang X, Ma L, Iwakiri Y, Chen L, Tang X, Chen Y*, Chen H*, Duan Y*. Nogo-B inhibition facilitates cholesterol metabolism to reduce hypercholesterolemia. Cell Rep. 2024;43(9):114691.
2. Gong K#, Xue C#, Feng Z, Pan R, Wang M, Chen S, Chen Y, Guan Y, Dai L, Zhang S, Jiang L, Li L, Wang B, Yin Z, Ma L, Iwakiri Y, Tang J, Liao C, Chen H, Duan Y*. Intestinal Nogo-B reduces GLP1 levels by binding to proglucagon on the endoplasmic reticulum to inhibit PCSK1 cleavage. Nat Commun. 2024;15(1):6845.
3. Jiaqi Li#,Shuang Zhang #,Yuyao Sun,Jian Li, Zian Feng, Huaxin Li, Mengxue Zhang, Tengteng Yan, Jihong Han, Yajun Duan.Liver ChREBP deficiency inhibits fructose-induced insulin resistance in pregnant mice and female offspring.EMBO Rep. 2024 Apr;25(4):2097-2117doi: 10.1038/s44319-024-00121-w. Epub 2024 Mar 26.
4. Yang Y#, Feng K#, Yuan L, Liu Y, Zhang M, Guo K, Yin Z, Wang W, Zhou S, Sun H, Yan K, Yan X, Wang X, Duan Y*, Hu Y*, Han J*. Compound Danshen Dripping Pill inhibits hypercholesterolemia/atherosclerosis-induced heart failure in ApoE and LDLR dual deficient mice via multiple mechanisms. Acta Pharmaceutica Sinica B. 2023;13(3):1036-1052.
5. Duan Y, Gong K, Xu S, Zhang F, Meng X, Han J*. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduct Target Ther. 2022;7(1):265. doi: 10.1038/s41392-022-01125-5. Review
6. Chen Y#, Hu W#, Li Q, Zhao S, Zhao D, Zhang S, Wei Z, Yang X, Chen Y, Li X, Liao C, Han J, Miao QR*, Duan Y*. NGBR is required to ameliorate type 2 diabetes in mice by enhancing insulin sensitivity. J Biol Chem. 2021;296:100624.
7. Feng K#, Ma C#, Liu Y, Yang X, Yang Z, Chen Y, Xu T, Yang C, Zhang S, Li Q, Wei Z, Zhao D, Zeng P, Han J, Gao J*, Chen Y*, Duan Y*. Encapsulation of LXR ligand by D-Nap-GFFY hydrogel enhances LXR anti-tumorigenic actions and removes LXR-induced lipogenesis. Theranostics 2021;11:2634-2654.
8. Zhang S, Guo F, Yu M, Yang X, Yao Z, Li Q, Wei Z, Feng K, Zeng P, Zhao D, Li X, Zhu Y, Miao QR, Iwakiri Y, Chen Y*, Han J*, Duan Y*. Reduction of Nogo-B expression deficiency protects mice against high-carbohydrate diet-induced hepatic metabolic disorders by regulating ChREBP and insulin activity. J Hepatol. 2020; 73(6):1482-1495.
9. Zhang S#, Yu M#, Guo F, Yang X, Chen Y, Ma C, Li Q, Wei Z, Li X, Wang H, Hu H, Zhang Y, Kong D, Miao Q, Hu W, Hajjar DP, Zhu Y, Han J*, Duan Y*. Rosiglitazone alleviates a-naphthylisothiocyanate-induced intrahepatic cholestasis in mice – The role of circulating 15d-PGJ2 and Nogo. Br J Pharmacol. 2020;177(5): 1041-1060.
10. Wang D#, Yang X#, Chen Y, Gong K, Yu M, Gao Y, Wu X, Hu H, Liao C, Han J*, Duan Y*. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression. J Biol Chem. 2020; 295(47):15870-15882.
Ongoing Projects (Limited to Principal Investigator)
Project origin and title | Total funding (in ten thousand yuan) | Start and End Date |
Study on the effect mechanism and intervention strategy of coronary artery calcification by fatty acid metabolism disorders via GPR31. | 255 | 2023-01 至2026-12 |
Study on the role and mechanism of liver NgBR preventing atherosclerosis by regulating lipid metabolism. | 55 | 2022-01 至2025-12 |
Research and promotion of integrated prevention system of panvascularization diseases. | 70 | 2022-01 至2024-11 |
Admission directions
Biology (Biochemistry, Cell Biology)
Biological and Pharmaceutical Engineering
Contact Information
E-mail: yajunduan@ustc.edu.cn